Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Non-cash Items (2018 - 2025)

AC Immune (ACIU) reported Non-cash Items of $3222.6 billion for Q4 2025, up 104.88% year-over-year from $1572.9 billion in Q4 2024, and up 104.88% on a QoQ basis from $1572.9 billion in Q4 2024.

AC Immune (ACIU) has 5 years of Non-cash Items data on file, last reported at $3222.6 billion in Q4 2025.

  • Quarterly Non-cash Items rose 104.88% year-over-year to $3222.6 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3222.6 billion (up 104.88% YoY) and the FY2025 annual result came in at $3106.6 billion, up 97.51% from the prior year.
  • Non-cash Items rose to $3222.6 billion in Q4 2025 per ACIU's latest filing, from $1572.9 billion in the prior quarter.
  • Across five years, Non-cash Items topped out at $3222.6 billion in Q4 2025 and bottomed at $336.9 billion in Q4 2023.
  • The 3-year median for Non-cash Items is $1572.9 billion (2024), against an average of $1710.8 billion.
  • The widest annual swing landed in 2024, when Non-cash Items surged 366.81%; it then soared 104.88% in 2025.
  • Tracing ACIU's Non-cash Items over 3 years: stood at $336.9 billion in 2023, then surged by 366.81% to $1572.9 billion in 2024, then soared by 104.88% to $3222.6 billion in 2025.
  • Per Business Quant, the three latest ACIU Non-cash Items figures stand at $3222.6 billion (Q4 2025), $1572.9 billion (Q4 2024), and $336.9 billion (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 AC Immune 325.88 Mn 211.53 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 3,222.63 Bn
Dec 31, 2025 3,222.63 Bn
Dec 31, 2024 1,572.91 Bn
Dec 31, 2024 1,572.91 Bn
Dec 31, 2023 336.95 Bn
Dec 31, 2023 336.95 Bn
Sep 30, 2019 7.98 Mn
Sep 30, 2019 7.98 Mn
Jun 30, 2019 7.53 Mn
Jun 30, 2019 7.53 Mn
Sep 30, 2018 6.79 Mn
Sep 30, 2018 6.79 Mn
Jun 30, 2018 6.68 Bn
Jun 30, 2018 6.68 Bn